✦ LIBER ✦

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

✍ Scribed by Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños, Claus-Henning Köhne

Book ID: 119897481
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 226 KB
Volume: 12
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-12-438

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line sunitinib plus FOLFIRI in Jap

First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study

✍ Yasushi Tsuji; Taroh Satoh; Akihito Tsuji; Kei Muro; Motoki Yoshida; Tomohiro Ni 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

An Open-label, Single-arm, Phase 2 Trial

An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer

✍ Allen L. Cohn; Grace C. Shumaker; Pankaj Khandelwal; David A. Smith; Marcus A. N 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 429 KB

14LBA Randomized phase 3 study of panitu

14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

✍ M. Peeters; T. Price; Y. Hotko; A. Cervantes; M. Ducreux; T. André; E. Chan; F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6073 Interim analysis of epidermal-growt

6073 Interim analysis of epidermal-growth factor receptor (EGFR) expression in a single-arm, phase II, first-line study (20060314) of panitumumab with FOLFIRI in the management of metastatic colorectal cancer (mCRC)

✍ Koehne, C.; Hofheinz, R.; Mineur, L.; Letocha, H.; Greil, R.; Thaler, J.; Gameli 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

PCN69 COST-EFFECTIVENESS OF FIRST-LINE C

PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

✍ M Gyldmark; R Aultman; U Siebert; E Sabate 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Phase II study of capecitabine plus oxal

Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer

✍ Yu Hong Li; Hui Yan Luo; Feng Hua Wang; Zhi Qiang Wang; Miao Zhen Qiu; Yan Xia S 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 234 KB